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*Clostridium difficile* infection (CDI) is one of the most common hospital-acquired infections and the leading cause of antibiotic-associated diarrhea and pseudomembranous colitis ([@B1]). Increasing CDI incidence rates have been mainly attributed to successful clones belonging to a few predominant ribotypes (RTs), with different distribution in different geographic regions ([@B2], [@B3]).

RT018 has been reported as one of the most prevalent genotypes circulating in hospital settings in Italy ([@B4], [@B5]) and in the Far East (i.e., South Korea and Japan) ([@B6], [@B7]) but has been rarely described in other countries ([@B2], [@B8]). RT018 is highly transmissible and generally shows a multidrug-resistant phenotype. It produces both toxin A and toxin B, but is negative for binary toxin, and is associated with complicated outcomes ([@B4], [@B7], [@B9]). In this report, we announce the draft genome of *C. difficile* CD8-15 belonging to RT018, which was isolated from a patient admitted to a hospital in Florence (central Italy) in 2015 with fatal *C. difficile*-associated infection evolved as toxic megacolon.

*C. difficile* CD8-15 was grown in 5 ml of thioglicollate broth and incubated under anaerobic conditions for 48 h at 37°C. Genomic DNA was subjected to whole-genome sequencing with the MiSeq platform (Illumina Inc., San Diego, CA, USA) using a 2×300-bp paired-end approach. A total of 2,118,990 reads were generated and then *de novo* assembled using SPAdes version 3.6.1 ([@B10]) into 44 scaffolds (largest scaffold = 831,956 bp; *N*~50~ = 235,991 bp; *L*~50~ = 5; average GC = 28.63%), with an estimated genome size of 4,249,791 bp and an average coverage of 50×.

The draft genome was then subjected to the following *in silico* analyses: (i) multilocus sequence typing (MLST; <http://pubmlst.org/cdifficile>); (ii) toxinotyping (<http://www.mf.uni-mb.si/mikro/tox>); (iii) detection of antibiotic resistance mechanisms, using the *C. difficile* 630 strain ([@B11]). The presence of phage-related sequences and CRISPR-Cas systems were investigated using PHAST (<http://phast.wishartlab.com>) and CRISPRFinder (<http://crispr.u-psud.fr>), respectively.

MLST analysis assigned *C. difficile* CD8-15 to sequence type (ST) 17, as previously reported for other *C. difficile* strains belonging to RT018 ([@B12], [@B13]). ST17 and other STs of *C. difficile* belong to clade I ([@B12]). Toxinotyping classified *C. difficile* CD8-15 as a nonvariant strain (toxinotype 0) producing toxin A and toxin B but not binary toxin CDT.

*C. difficile* CD8-15 was resistant to rifampin (MIC \>32 mg/L), levofloxacin (MIC \>32 mg/L), and erythromycin (MIC \>256 mg/L) but remained susceptible to clindamycin (MIC 2 mg/L). Sequence analysis revealed the presence of point mutations in the *rpoB* gene (R505K and I548M), which is known to be associated with high-level resistance to rifamycins ([@B14]). Mutations were detected also in the quinolone resistance-determining region of *gyrA* (T82I), which is consistent with the fluoroquinolones resistance phenotype. Resistance to erythromycin was likely attributable to the presence of a multidrug efflux system encoded by the *cme* gene ([@B15]), while *erm* genes and other genes involved in macrolides resistance (i.e., *mef*, *msr, cfr*) were not detected ([@B9], [@B16]). PHAST identified 3 intact and 5 incomplete prophage regions. CRISPRFinder identified two class I CRISPR-Cas systems.
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This whole-genome shotgun project has been deposited at DDBJ/EMBL/GenBank under the accession number [LYDP00000000](http://www.ncbi.nlm.nih.gov/nuccore/LYDP00000000).
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